RESUMEN
The authors tested the safety and efficacy of intravenous metoclopramide in the prevention of chemotherapy-induced nausea and vomiting. Those studied included hospitalized patients receiving their initial treatment with potent, emetogenic non-cisplatin-containing regimens, and outpatients receiving both their initial and maintenance non-cisplatin-containing chemotherapy. Fifty patients received metoclopramide with one or more of three intravenous metoclopramide dosage schedules, based on whether they received their chemotherapy on an inpatient or outpatient basis. Of the 50 patients treated, 39 (78%) achieved total protection (no emesis), and 9 (18%) attained major antiemetic protection (one or two emeses) when all dosage schedules of metoclopramide were combined. Therefore, total or major antiemetic protection was observed in 48 of 50 patients (96%) receiving a broad range of potentially emetogenic chemotherapy. Antiemetic protection was shown not to depend on the schedule of metoclopramide dosing used, but rather on the emetic potential of the chemotherapeutic agents or combinations employed. In addition, previously treated patients in whom chemotherapy-related nausea or vomiting had posed a significant problem in the past, were shown to have an overall lower incidence of total antiemetic and antinausea protection as compared with patients who were previously untreated or did not experience emesis with prior chemotherapy. Thirty patients experienced no nausea or vomiting with intravenous metoclopramide; in the 20 patients who experienced nausea, its incidence was shown to be directly proportional to the emetic potential of the chemotherapy agents employed. Side effects were dose-related, however none were serious enough to warrant drug withdrawal. It is concluded that intravenous metoclopramide possesses significant antiemetic activity in patients receiving potent, non-cisplatin-containing chemotherapy. The dosage and scheduling required to provide total protection against nausea and vomiting appears to be dependent on the inherent emetic potency of the chemotherapy used. Further studies involving large numbers of patients are required to determine the optimal dosage and scheduling of this agent.
Asunto(s)
Antineoplásicos/efectos adversos , Metoclopramida/administración & dosificación , Náusea/prevención & control , Vómitos/prevención & control , Diarrea/inducido químicamente , Esquema de Medicación , Evaluación de Medicamentos , Humanos , Infusiones Parenterales , Metoclopramida/efectos adversos , Persona de Mediana Edad , Náusea/inducido químicamente , Fases del Sueño/efectos de los fármacos , Vómitos/inducido químicamenteRESUMEN
Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively. The survival curves for both groups of patients were similar, with a median survival of 32 months. At 36 months, 70% of those patients who obtained good response were alive, 29% of those with partial response were alive, and 13% of those with no response were alive. The clinical staging system described by Durie and Salmon shows a good prognosis for stage I patients, with 80% remaining alive at 48 months, while the survival curves for stage II and III patients were similar, with 33% and 28% respectively remaining alive at 48 months. The combination of methyl-CCNU-cyclophosphamide-prednisone is not more effective in terms of response rate or duration of survival than melphalan-prednisone.
Asunto(s)
Antineoplásicos/administración & dosificación , Mieloma Múltiple/tratamiento farmacológico , Adulto , Anciano , Ensayos Clínicos como Asunto , Ciclofosfamida/administración & dosificación , Quimioterapia Combinada , Humanos , Melfalán/administración & dosificación , Persona de Mediana Edad , Estadificación de Neoplasias , Prednisona/administración & dosificación , Pronóstico , Semustina/administración & dosificación , Factores de TiempoAsunto(s)
Antineoplásicos/administración & dosificación , Enfermedad de Hodgkin/tratamiento farmacológico , Adolescente , Adulto , Ensayos Clínicos como Asunto , Ciclofosfamida/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Enfermedad de Hodgkin/radioterapia , Humanos , Lomustina/administración & dosificación , Masculino , Persona de Mediana Edad , Prednisona/administración & dosificación , Procarbazina/administración & dosificación , Remisión Espontánea , Vinblastina/administración & dosificaciónRESUMEN
Foi o raio laser aplicado em caes, em quatro tipos de experiencia: 1)lesao da intima e media das arterias, provando-se a inexistencia de estenose e formacao de trombos ate com 20 dias de evolucao; 2) "sutura" arterial ou arteriopatia, demonstrando-se a completa hemostasia e a alta resistencia a rotura, em experiencias agudas e cronicas de ate 17 dias; 3) anastomoses arterio-arteriais e arterio-venosas, mostrando-se a permeabilidade da luz dos vasos, a nao producao de estenose e trombos; 4) a - possibilidade de usar o laser, conduzido por cateter, sem necessidades de interromper a circulacao no sistema cardiovascular; b - eliminacao da estenose pulmonar, atraves do cateterismo cardiaco. Com estes resultados, acreditam os autores que o uso do laser em Cardiologia-Clinica possa ser iniciado